Our flagship product, Engensis (VM202), is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF) through simple intramuscular injections. Engensis is being studied in clinical trials to determine whether it can provide safe and efficacious treatment effects for diabetic peripheral neuropathy (DPN), diabetic foot ulcer (DFU), and coronary artery disease (CAD) among other indications. Th...
Our flagship product, Engensis (VM202), is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF) through simple intramuscular injections. Engensis is being studied in clinical trials to determine whether it can provide safe and efficacious treatment effects for diabetic peripheral neuropathy (DPN), diabetic foot ulcer (DFU), and coronary artery disease (CAD) among other indications. The US FDA has granted orphan drug and fast track designations for Engensis for the potential treatment of Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.